The Zimmer Biomet Holdings Inc (ZBH) Now Covered by Goldman Sachs Group Inc

The Zimmer Biomet Holdings Inc (ZBH) Now Covered by Goldman Sachs Group Inc

ZBH has been the topic of a number of other reports. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Thursday, April 13th. Canaccord Genuity set a $130.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Monday, January 23rd. Royal Bank of Canada boosted their price target on Zimmer Biomet Holdings from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, February 1st. Wells Fargo & Co lowered Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research note on Friday, April 28th. Finally, Needham & Company LLC boosted their price target on Zimmer Biomet Holdings from $148.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Wednesday, January 25th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $133.82.

Research analysts at Goldman Sachs Group Inc initiated coverage on shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) in a report issued on Tuesday, May 16th. The brokerage set a “sell” rating and a $92.00 price target on the medical equipment provider’s stock. Goldman Sachs Group Inc’s price target indicates a potential downside of 25.77% from the company’s previous close.

Shares of Zimmer Biomet Holdings (ZBH) traded up 1.04% on Tuesday, reaching $123.94. The company’s stock had a trading volume of 1,394,223 shares. The company has a 50 day moving average of $119.96 and a 200 day moving average of $114.46. The stock has a market capitalization of $24.99 billion, a P/E ratio of 50.73 and a beta of 1.20. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.66% and a net margin of 3.90%. The company had revenue of $1.98 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter in the previous year, the firm earned $2.00 earnings per share. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Equities research analysts expect that Zimmer Biomet Holdings will post $8.54 earnings per share for the current fiscal year. The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 23rd will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 65.31%.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.66% and a net margin of 3.90%. The company had revenue of $1.98 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter in the previous year, the firm earned $2.00 earnings per share. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Equities research analysts expect that Zimmer Biomet Holdings will post $8.54 earnings per share for the current fiscal year. In other Zimmer Biomet Holdings news, insider David C. Dvorak sold 87,331 shares of the stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $116.47, for a total transaction of $10,171,441.57. Following the completion of the transaction, the insider now owns 381,886 shares in the company, valued at approximately $44,478,262.42. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Chad F. Phipps sold 6,200 shares of the stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $116.76, for a total value of $723,912.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,571 shares of company stock valued at $11,021,849. 1.22% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. Johnson Financial Group Inc. increased its position in Zimmer Biomet Holdings by 17.4% in the fourth quarter. Johnson Financial Group Inc. now owns 977 shares of the medical equipment provider’s stock worth $100,000 after buying an additional 145 shares in the last quarter. Parkside Financial Bank & Trust increased its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Independent Advisor Alliance acquired a new position in Zimmer Biomet Holdings during the fourth quarter worth approximately $103,000. Capital Guardian Trust Co. increased its stake in shares of Zimmer Biomet Holdings by 52.1% in the fourth quarter. Capital Guardian Trust Co. now owns 1,229 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 421 shares during the period. Finally, Acrospire Investment Management LLC purchased a new stake in shares of Zimmer Biomet Holdings during the third quarter valued at about $130,000. Institutional investors own 86.62% of the company’s stock. About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “ZBH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment